$NTLA Perking Up
Genome editor Intellia Therapeutics poised for new highs after pulling back from high-volume charge at this mark Wednesday. Strong sales, less than desirable earnings and cash flow, but perhaps the momentum is gaining there.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.